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ABSTRACT	  
	  Ginger	  (Zingiber	  Officinale)	  has	  been	  used	  in	  Asia	  for	  centuries	  to	  treat	  various	  ailments.	  Ginger	  has	  been	  reported	  to	  alleviate	  migraine	  pain	  via	  four	  bioactive	  compounds	  that	  can	  reduce	  nitric	  oxide	  synthase	  (NOS)	  resulting	  in	  the	  inhibition	  of	  nitric	  oxide	  (NO).	  The	  inhibition	  of	  nitric	  oxide	  results	  in	  the	  vasoconstriction	  of	  the	  intracranial	  blood	  vessels	  alleviating	  migraine	  pain.	  It	  is	  hypothesized	  that	  ginger	  has	  structural	  similarities	  to	  vasoconstrictor	  drugs	  causing	  similar	  receptor	  interactions.	  	  A	  review	  of	  the	  bioactive	  compounds	  in	  ginger	  and	  popular	  vasoconstrictor	  drugs	  was	  done	  to	  determine	  structural	  similarities.	  The	  results	  of	  this	  study	  show	  that	  the	  compounds	  in	  ginger	  share	  no	  structural	  similarities	  with	  vasoconstrictor	  drugs	  used	  in	  the	  treatment	  of	  migraine	  headaches.	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CHAPTER	  ONE:	  INTRODUCTION	  A	  migraine	  is	  characterized	  as	  a	  moderate	  to	  severe	  throbbing	  pain	  with	  symptoms	  of	  nausea,	  vomiting,	  sensitivity	  to	  light	  (photophobia),	  sound	  (phonophobia)	  and	  head	  movements.1	  Migraines	  affect	  12%	  of	  the	  population	  and	  result	  in	  decreased	  work	  productivity	  and	  performance.	  In	  2004,	  the	  Headache	  Classification	  Committee	  of	  International	  Headache	  Society	  (IHS)	  published	  a	  paper	  with	  a	  new	  classification	  of	  migraines	  called	  ‘migraines	  with	  aura.'	  The	  original	  migraine	  definition	  was	  kept	  the	  same,	  however	  ‘migraine	  with	  aura'	  was	  used	  to	  define	  a	  migraine	  in	  which	  reversible	  loss	  of	  vision,	  speech,	  and	  sensory	  occur.2	  	  	  Migraines	  arise	  by	  activation	  of	  serotonin	  receptors	  leading	  to	  the	  release	  of	  NO	  (nitric	  oxide)	  resulting	  in	  vasodilation.	  NO	  can	  further	  induce	  vasodilation	  by	  the	  release	  of	  neurotransmitters	  such	  as	  calcitonin	  gene-­‐related	  peptide	  (CGRP)	  and	  substance	  P.	  Ginger	  can	  alleviate	  migraine	  pain	  due	  to	  its	  ability	  to	  inhibit	  NO	  resulting	  in	  vasoconstriction.	  15-­‐16	  These	  findings	  suggest	  that	  ginger	  may	  have	  structural	  similarities	  to	  vasoconstrictor	  drugs.	  	  This	  study	  seeks	  to	  determine	  whether	  the	  compounds	  in	  ginger	  share	  structural	  similarities	  to	  vasoconstrictor	  drugs.	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CHAPTER	  TWO:	  LITERATURE	  REVIEW	  
2.1	  Migraine	  History	  	  In	  1938,	  Harold	  Wolff	  established	  the	  first	  migraine	  theory	  known	  as	  the	  vascular	  theory.	  Wolff	  found	  that	  patients	  with	  migraines	  had	  extracranial	  vasodilation	  that	  could	  be	  treated	  by	  using	  vasoconstrictors.	  Wolff	  concluded	  that	  vasodilation	  results	  in	  migraine	  pain	  and	  vasoconstriction	  could	  be	  used	  to	  alleviate	  the	  pain.3	  After	  this	  finding,	  DeVries	  suggested	  that	  vascular	  pulsation	  leads	  to	  activation	  of	  stretch	  receptors	  causing	  the	  release	  of	  neuropeptides	  such	  as	  calcitonin	  gene-­‐related	  peptide	  (CGRP)	  from	  perivascular	  nerves.	  CGRP	  is	  a	  potent	  vasodilator,	  which	  can	  lead	  to	  migraine	  pain.4	  Although	  the	  vascular	  theory	  was	  initially	  believed	  to	  be	  the	  only	  mechanism	  of	  action	  by	  which	  migraines	  arise,	  another	  theory	  was	  created	  which	  further	  expands	  on	  the	  pathology	  of	  a	  migraine.	  	  	  In	  1983,	  James	  W.	  Lance	  showed	  that	  the	  blood	  flow	  changes	  in	  migraines	  could	  be	  created	  by	  stimulation	  of	  the	  brain	  stem	  leading	  to	  the	  formation	  of	  the	  neurogenic	  theory.5	  In	  1993,	  Moskowitz	  further	  supported	  this	  argument	  by	  publishing	  a	  study	  on	  the	  inflammation	  of	  the	  dural	  membrane.	  Moskowitz	  noticed	  that	  the	  release	  of	  vasopeptides	  from	  the	  trigeminal	  axons	  of	  the	  dura	  (outer	  layer	  of	  the	  meninges	  which	  is	  the	  membrane	  covering	  brain	  and	  spinal	  cord)	  and	  pia	  (inner	  layer	  of	  the	  meninges)	  mater	  produced	  an	  inflammatory	  reaction	  with	  pain.6	  This	  inflammatory	  response	  stimulates	  the	  trigeminal	  ganglion	  causing	  protein	  extravasation	  (protein	  leakage).	  The	  proteins	  released	  are	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vasoactive	  peptides	  such	  as	  calcitonin	  gene-­‐related	  peptides	  (CGRP)	  and	  substance	  P.7	  These	  two	  vasoactive	  peptides	  play	  vital	  roles	  in	  dural	  inflammation	  because	  substance	  P	  causes	  protein	  extravasation	  (protein	  leakage).	  CGRP	  works	  synergistically	  with	  substance	  P	  by	  increasing	  blood	  flow	  in	  the	  dura	  and	  inhibiting	  metabolism	  of	  substance	  P	  resulting	  in	  dural	  inflammation	  and	  nerving	  ending	  irritation.8	  Based	  on	  these	  findings	  the	  neurogenic	  theory	  demonstrated	  that	  vascular	  changes	  result	  in	  inflammation	  and	  vasodilation	  of	  dural	  membrane	  causing	  a	  migraine.	  	  	  Two	  major	  theories	  were	  established	  that	  explained	  the	  mechanism	  of	  migraines,	  however,	  these	  did	  not	  account	  for	  ‘migraine	  with	  aura’.	  This	  phenomenon	  was	  addressed	  in	  the	  neurological	  theory,	  which	  states	  that	  ‘migraine	  with	  aura’	  is	  caused	  by	  depolarization	  of	  cortical	  neurons	  from	  the	  occipital	  lobe	  (back	  of	  the	  head)	  toward	  the	  frontal	  lobe.9	  Depolarization	  of	  the	  cortical	  neurons	  results	  in	  sensory	  or	  motor	  impairment	  leading	  to	  loss	  of	  vision,	  speech	  symptoms,	  and	  sensory	  symptoms.10	  This	  process	  is	  called	  cortical	  spreading	  depression	  (CSD).	  CSD	  is	  typically	  coupled	  with	  a	  period	  of	  hyperemia	  (increased	  blood	  volume)	  followed	  by	  a	  period	  of	  oligemia	  (decrease	  blood	  volume).	  Studies	  suggest	  that	  a	  catalyst	  of	  CSD	  is	  nitric	  oxide	  (NO),	  a	  potent	  vasodilator.10	  	  	  Although	  not	  much	  is	  understood	  on	  migraines,	  these	  three	  theories	  (vascular,	  neurogenic,	  neurological)	  help	  to	  provide	  insight	  on	  the	  modes	  of	  action	  of	  migraine.	  	  The	  following	  literature	  review	  will	  focus	  on	  the	  connection	  between	  migraines	  and	  ginger	  (vasoconstrictor).	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2.2	  Relationship	  between	  serotonergic	  receptors,	  nitric	  oxide,	  and	  calcitonin	  gene-­‐related	  
peptide	  in	  migraines	  
	  The	  5-­‐hydroxytryptamine	  (5-­‐HT)	  receptor	  is	  a	  serotonin	  receptor	  that	  has	  been	  reported	  to	  control	  migraines	  via	  ligand-­‐receptor	  interactions.	  11	  For	  example,	  a	  recent	  study	  has	  shown	  that	  when	  the	  5-­‐HT2A	  receptor	  is	  activated	  it	  causes	  pain,	  inflammation,	  and	  vasodilation.	  Initial	  interest	  in	  this	  receptor	  occurred	  in	  an	  experiment	  where	  researchers	  noticed	  an	  increase	  in	  5-­‐HT2A	  (ligand)	  on	  a	  platelet	  membrane	  of	  a	  migraine	  patient.12	  This	  observation	  had	  motivated	  scientists	  to	  determine	  the	  relationship	  between	  the	  5-­‐HT2A	  receptor	  and	  the	  nitric	  oxide	  (NO)	  system.	  NO	  is	  an	  essential	  factor	  in	  the	  development	  of	  	  migraines	  due	  to	  its	  ability	  to	  cause	  vasodilation,	  which	  was	  shown	  in	  a	  study	  using	  nitroglycerin	  (NO	  donor)	  to	  induce	  migraines.	  13	  	  	  In	  order	  to	  determine	  the	  relationship	  between	  nitric	  oxide	  and	  HT2A	  receptor,	  two	  experiments	  were	  carried	  out.	  The	  first	  experiment	  determined	  the	  effects	  of	  5-­‐HT2A	  receptor	  agonist	  1,2,5-­‐dimethoxy-­‐4-­‐iodophenyl-­‐2-­‐aminopropane	  (DOI)	  on	  chemical	  (discomfort	  pain	  sensation)	  and	  thermal	  nociception	  (burning	  pain).	  While	  the	  second	  experiment	  conducted,	  investigated	  the	  effect	  of	  DOI	  on	  regional	  cerebral	  blood	  flow	  and	  NOS	  (nitric	  oxide	  synthase)	  expression	  in	  the	  trigeminovascular	  nerve	  fibers	  and	  neurons.	  These	  experiments	  were	  run	  on	  mice,	  which	  would	  be	  dissected,	  and	  immunohistochemically	  studied.	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The	  results	  of	  these	  two	  experiments	  showed	  that	  the	  5-­‐HT	  receptor	  caused	  cerebral	  hyperemia	  (increased	  blood	  flow	  in	  the	  brain)	  and	  increased	  nitric	  oxide	  synthase	  (NOS)	  expression	  in	  trigeminal	  ganglion	  and	  trigeminal	  nucleus	  caudalia.	  	  Additionally,	  researchers	  found	  that	  the	  5-­‐HT2A	  receptors	  activated	  by	  DOI	  caused	  activation	  of	  trigeminovascular	  NO	  pathway	  similarly	  to	  mice	  injected	  with	  nitroglycerin	  (NTG),	  a	  nitric	  oxide	  donor	  that	  causes	  migraines.	  DOI	  activates	  the	  NO	  pathway	  by	  increasing	  NOS	  cells	  in	  the	  trigeminal	  nerves.	  These	  findings	  lead	  to	  the	  conclusion	  that	  nitric	  oxide	  synthesis	  occurs	  by	  activation	  of	  the	  5-­‐HT2A	  receptor.	  The	  5-­‐HT2A	  receptor	  causes	  an	  increase	  in	  intracellular	  calcium	  resulting	  in	  activation	  of	  NOS	  pathway.	  NOS	  allows	  the	  release	  of	  NO	  from	  neurons.	  Once	  released,	  NO	  diffuses	  back	  into	  the	  presynaptic	  terminal	  to	  release	  neurotransmitters	  such	  as	  substance	  P	  and	  CGRP.14	  These	  findings	  suggest	  a	  link	  between	  NO	  and	  CGRP,	  which	  is	  supported	  by	  two	  studies	  that	  demonstrated	  NO-­‐donor-­‐triggered	  migraines	  cause	  an	  increase	  of	  CGRP	  even	  when	  blocked	  by	  sumatriptan.15,	  16	  	  	  The	  5-­‐HT2A	  receptor	  can	  also	  be	  down	  regulated	  via	  drugs	  result	  in	  the	  alleviation	  of	  migraines.	  Furthermore,	  the	  5-­‐HT2A	  receptor	  is	  not	  the	  only	  type	  of	  serotonin	  receptor	  that	  can	  alleviate	  migraines.	  The	  genes	  in	  our	  body	  code	  for	  different	  types	  of	  serotonin	  receptors	  each	  with	  a	  unique	  mechanism	  of	  action	  and	  effect	  on	  migraines,	  which	  can	  be	  seen	  in	  Table	  1.	  Some	  receptors	  have	  subclasses	  with	  the	  same	  result	  but	  are	  just	  encoded	  by	  different	  genes.	  For	  example,	  HTR1A	  gene	  encodes	  the	  HT1A	  receptor,	  while	  HTR1B	  gene	  encodes	  the	  HT1B	  receptor.17-­‐19	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Table	  1:	  Classification	  of	  Serotonin	  Receptors	  
Receptor	   Subclasses	   Ligand	  Type	   Mechanism	  of	  
action	  
Effect	  	  
5-­‐HT1	   5-­‐HT1A,	  B,	  D,	  E,	  F	   Agonist	   Allows	  the	  decrease	  of	  cyclic	  adenosine	  monophosphate	  (cAMP)	  	  
Induces	  vasoconstriction	  and	  reduces	  inflammation	  by	  inhibition	  of	  substance	  (CGRP,	  substance	  P,	  NO)	  from	  trigeminal	  nerve	  causing	  redistribution	  of	  blood	  flow	  resulting	  in	  alleviation	  of	  migraine	  pain.	  
5-­‐HT2	   5-­‐HT2A,	  B,	  C	   Antagonist	   Allows	  the	  increase	  levels	  of	  IP3	  and	  DAG	  	   Prevents	  increase	  of	  intracellular	  calcium	  resulting	  decrease	  of	  	  nitric	  oxide	  causing	  vasoconstriction	  causing	  alleviation	  of	  migraine	  pain	  
5-­‐HT3	   N/A	   Antagonist	   Prevents	  depolarization	  of	  the	  plasma	  membrane	   	  Reduce	  vascular	  pain	  caused	  by	  inflammation	  and	  inhibition	  of	  substance	  (CGRP	  and	  substance	  P	  from	  the	  trigeminal	  nerve.	  	  	  
5-­‐HT4	   N/A	   Agonist	   Allows	  increase	  of	  cyclic	  adenosine	  monophosphate	  (cAMP)	  
Intracranial	  vasoconstriction	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2.3	  Components	  of	  Ginger	  
	  Table	  2:	  Species	  of	  Ginger	  
Species	  of	  Medicinal	  Ginger	   Origin	  
Jamaican	  Ginger	   Jamaica	  
Zingiber	  Officinale	  Roscoe	  	   Western	  nations	  (USA)	  
Shokoyo	  	  
(dried	  rhizome	  of	  Z.	  Officinale	  var.	  rubens)	  
Japan	  
Kankyo	  
(steamed	  and	  dried	  rhizome	  of	  Z.	  officinale	  var	  rubens)	  
Japan	  
Red	  ginger	  	  
(rhizome	  of	  Z.	  officinale	  var.	  rubra)	  
Indonesia	  
White	  ginger	  	  
(rhizome	  of	  Z.	  officinale	  var	  amarum)	  
Indonesia	  
	  Ginger	  is	  a	  member	  of	  the	  plant	  family	  Zingiberaceae	  and	  can	  be	  found	  in	  many	  different	  species	  as	  shown	  in	  Table	  2.20-­‐21	  However,	  the	  species	  that	  has	  been	  studied	  is	  Zingiber	  
Officinale	  Roscoe.	  Ginger	  has	  been	  shown	  to	  have	  at	  least	  115	  constituents	  in	  fresh	  and	  dried	  ginger.	  It	  is	  important	  to	  note	  that	  the	  individual	  components	  in	  ginger	  depend	  on	  the	  origin,	  processor,	  and	  whether	  it	  is	  fresh,	  dried,	  or	  processed.22	  Methanolic	  extractions	  have	  been	  used	  to	  isolate	  31	  compounds	  in	  fresh	  ginger.23	  Of	  these	  isolated	  compounds,	  14	  bioactive	  compounds	  have	  been	  found.	  These	  bioactive	  compounds	  are	  [4]-­‐gingerol,	  [6]-­‐
5-­‐HT7	   N/A	   Antagonist	   Allow	  increase	  of	  cyclic	  adenosine	  monophosphate	  (cAMP)	  
Decreases	  level	  of	  CGRP	  and	  substance	  p	  resulting	  in	  vasoconstriction	  relieving	  migraine	  pain	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gingerol,	  [8]-­‐gingerol,	  [10]-­‐gingerol,	  [6]-­‐paradol,	  [14]-­‐shogaol,	  [6]-­‐shogaol,	  1-­‐dehydro-­‐[10]-­‐gingerdione,	  [10]-­‐gingerdione,	  hexahydrocurcumin,	  tetrahydrocurcumin,	  gingerenone	  A,	  1,7-­‐bis-­‐(4′	  hydroxyl-­‐3′	  methoxyphenyl)-­‐5-­‐methoxyhepthan-­‐3-­‐one,	  and	  methoxy-­‐[10]-­‐gingerol.24	  However	  in	  regards	  to	  migraines	  the	  following	  bioactive	  compounds	  shown	  below	  have	  been	  noted	  to	  act	  as	  potent	  antioxidants.25	  	  
 Figure	  1:	  Structure	  of	  [6]-­‐Gingerol	  
 Figure	  2:	  Structure	  of	  [6]-­‐Shogaol	  
 
  Figure	  3:	  Structure	  [1]-­‐Dehydro-­‐[10]-­‐gingerdione	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2.4	  Relationship	  of	  Ginger	  &	  Migraines	  	  The	  Chinese	  and	  Indians	  have	  used	  Ginger	  for	  over	  400	  years	  to	  treat	  colds,	  arthritis,	  nausea,	  hypertension,	  and	  migraines.	  Treatment	  of	  these	  ailments	  is	  due	  to	  the	  antioxidant,	  anti-­‐inflammatory,	  anti-­‐nausea,	  and	  anti-­‐carcinogenic	  properties	  of	  ginger.25	  However,	  to	  verify	  that	  ginger	  treats	  migraines	  a	  few	  studies	  have	  been	  done.	  For	  example,	  a	  study	  by	  Maghbooli	  compared	  the	  efficacy	  of	  ginger	  and	  sumatriptan	  (potent	  vasoconstrictor	  used	  to	  treat	  migraines)	  in	  a	  group	  of	  100	  men	  and	  women	  with	  acute	  migraine	  pain.	  The	  patients	  were	  given	  250	  mg	  of	  dried	  ginger	  powder	  or	  50	  mg	  sumatriptan.	  	  The	  participants	  recorded	  the	  time	  the	  headache	  began,	  headache	  severity	  before	  taking	  the	  capsule,	  and	  degree	  of	  pain	  relief	  afterward.	  The	  results	  showed	  that	  ginger	  was	  equally	  affective	  in	  relieving	  headaches	  while	  demonstrating	  minor	  digestive	  symptoms.26	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sublingual	  feverfew/ginger	  capsule	  found	  pain	  relief.	  	  This	  study	  showed	  that	  the	  sublingual	  ginger/feverfew	  is	  safe	  and	  should	  be	  used	  as	  the	  first	  line	  of	  defense	  for	  migraines.27	  	  	  In	  addition	  to	  these	  studies,	  Ippoushi	  has	  demonstrated	  ginger’s	  ability	  to	  inhibit	  NO.28	  However,	  before	  looking	  into	  this	  mechanism,	  a	  brief	  explanation	  of	  immunology	  is	  needed	  to	  understand	  the	  experiment.	  In	  our	  primary	  line	  of	  defense,	  macrophages	  detect	  pathogens	  resulting	  in	  the	  recruitment	  of	  other	  cells	  to	  the	  pathogen	  (inflammation)	  or	  destruction	  of	  the	  pathogen.	  Macrophages	  have	  pathogen	  recognition	  receptors	  (PRRs)	  that	  recognize	  pathogen-­‐associated	  molecular	  patterns	  (PAMPs)	  such	  as	  lipopolysaccharide	  (LPS).	  These	  macrophages	  will	  then	  bind	  to	  the	  pathogen	  and	  engulf	  them	  via	  phagocytosis.	  This	  results	  in	  the	  formation	  of	  a	  phagolysosome	  with	  in	  the	  macrophage.	  	  The	  macrophage	  can	  then	  release	  radical	  oxygen	  species	  with	  in	  the	  phagolysosome	  such	  as	  nitric	  oxide	  to	  kill	  the	  pathogen.	  29	  	  	  	  Ippoushi	  created	  a	  study,	  in	  which	  he	  could	  stimulate	  the	  production	  of	  nitric	  oxide	  by	  injecting	  mice	  with	  LPS.	  In	  this	  study,	  Ippoushi	  found	  that	  in	  the	  LPS-­‐stimulated	  macrophage,	  [6]-­‐gingerol	  inhibited	  NO	  production	  and	  reduced	  inducible	  nitric	  oxide	  synthase	  (iNOS),	  which	  is	  stimulated	  in	  response	  to	  stress.28	  Ippoushi's	  work	  was	  later	  complemented	  by	  a	  researcher	  named	  Koh,	  who	  showed	  that	  [6]-­‐shogaol,	  1-­‐dehydro-­‐[10]-­‐gingerdione,	  and	  [10]-­‐gingerdione	  decreased	  LPS-­‐induced	  NO	  production,	  and	  reduced	  iNOS	  expression.30	  This	  study	  shows	  that	  the	  bioactive	  compound	  in	  ginger	  can	  inhibit	  NO	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production,	  which	  results	  in	  vasoconstriction.	  This	  experiment	  is	  supported	  by	  the	  structural	  properties	  of	  the	  bioactive	  compounds	  shown	  above.	  The	  bioactive	  compounds	  of	  ginger	  are	  phenolic	  compounds,	  which	  can	  act	  as	  nitric	  oxide	  production	  inhibitors.31	  	  	  Ginger	  has	  also	  shown	  the	  ability	  to	  partially	  activate	  5-­‐HT1A,	  which	  induces	  vasoconstriction	  and	  reduces	  inflammation	  by	  inhibition	  of	  substances	  (CGRP,	  Substance	  P,	  NO)	  from	  trigeminal	  nerve	  causing	  redistribution	  of	  blood	  flow	  resulting	  in	  alleviation	  of	  migraine	  pain.32	  Based	  on	  this	  information	  it	  can	  be	  concluded	  that	  the	  bioactive	  compounds	  in	  ginger	  play	  a	  critical	  role	  in	  the	  inhibition	  of	  NO,	  which	  in	  turn	  play	  a	  role	  in	  the	  alleviation	  of	  migraines.	  	  
2.5	  Hypothesis	  and	  Intent	  	  The	  studies	  on	  the	  bioactive	  compounds	  of	  ginger	  suggest	  possible	  structural	  similarities	  to	  vasoconstrictor	  drugs	  used	  to	  treat	  migraines.	  Therefore,	  a	  comprehensive	  review	  is	  done	  to	  determine	  structural	  similarities.	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CHAPTER	  3:	  METHODOLOGY	  
	  
3.1	  Experimental	  approach	  	  	  Our	  approach	  from	  the	  beginning	  of	  this	  experiment	  was	  to	  do	  a	  comprehensive	  review	  on	  the	  mechanism	  of	  migraines.	  	  From	  this	  literature	  review,	  we	  learned	  about	  the	  role	  of	  5-­‐	  HT	  receptors,	  nitric	  oxide,	  calcitonin-­‐gene	  related	  peptide,	  and	  substance	  P	  in	  migraine	  headaches15,	  16,17,18.	  After	  establishing	  a	  background	  in	  migraines,	  the	  next	  goal	  of	  this	  project	  was	  to	  compile	  a	  list	  of	  references	  that	  discussed	  ginger	  as	  a	  treatment	  for	  migraine	  headaches.	  Once	  this	  list	  was	  collected,	  extensive	  research	  was	  done	  to	  determine	  whether	  these	  papers	  had	  scientific	  validity.	  	  After	  the	  scientific	  validity	  of	  ginger's	  role	  in	  a	  migraine	  was	  determined,	  it	  was	  essential	  to	  find	  the	  connection	  between	  the	  mechanism	  of	  ginger	  and	  migraines.	  	  Once	  the	  relationship	  between	  migraines	  and	  ginger	  was	  established,	  the	  final	  piece	  of	  the	  project	  required	  a	  compiled	  list	  of	  popular	  vasoconstrictor	  drugs	  and	  their	  mechanism	  of	  action	  against	  migraines.	  	  These	  drugs	  were	  then	  compared	  with	  bioactive	  compounds	  in	  ginger	  to	  determine	  any	  structural	  similarities.	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CHAPTER	  4:	  RESEARCH	  FINDINGS	  
	  
Review	  of	  vasoconstrictor	  drugs	  and	  mechanism	  of	  action	  against	  migraines	  	  
4.1	  Triptan	  Family	  	  The	  triptan	  family	  is	  a	  class	  of	  highly	  selective	  5-­‐HT	  receptor	  agonists	  whose	  actions	  can	  relieve	  migraines	  through	  vasoconstriction	  of	  intracranial	  blood	  vessels,	  inhibition	  of	  vasoactive	  neuropeptide	  release	  (CGRP),	  and	  blocking	  of	  pain	  signals.	  The	  onset	  action	  of	  these	  drugs	  typically	  ranges	  from	  30	  to	  60	  minutes.	  The	  most	  common	  triptan	  drugs	  used	  to	  treat	  migraines	  are	  Rizatriptan,	  Sumatriptan,	  Eletriptan,	  and	  Almotriptan,	  which	  can	  be	  seen	  in	  the	  figures	  below.33	   Figure	  5:	  Structure	  of	  Rizatriptan	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Figure	  6:	  Structure	  of	  Sumatriptan	  
	  
	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  Sumatriptan	  (Imitrex)	  is	  a	  5-­‐HT1B,	  1D	  receptor	  agonist	  that	  	  causes	  vasoconstriction	  of	  dilated	  arteries	  and	  decreases	  activity	  of	  the	  trigeminal	  nerve.33	  	  Figure	  7:	  Structure	  of	  Eletriptan	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   Figure	  8:	  Structure	  of	  Almotriptan	  	  
	   	   	  	  Almotriptan	  binds	  to	  the	  5-­‐HT1B,	  1D	  receptor	  with	  high	  affinity	  and	  leads	  to	  vasoconstriction	  of	  cranial	  blood	  flow,	  which	  causes	  redistribution	  of	  blood	  flow.33	  
4.2	  Elavil	  (Amitriptyline)	  
	   Figure	  9:	  Structure	  of	  Elavil	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4.3	  Metoclopramide	  	   Figure	  10:	  Structure	  of	  Metoclopramide	  	  
	   	  
	  Metoclopramide	  is	  a	  popular	  drug	  used	  to	  treat	  migraines	  due	  to	  its	  ability	  to	  act	  as	  a	  5-­‐HT3	  receptor	  antagonist	  and	  5-­‐HT4	  receptor	  agonist.	  Metoclopramide’s	  ability	  to	  act	  as	  a	  5-­‐HT3	  antagonist	  causes	  alleviation	  of	  pain	  by	  reduction	  of	  inflammation	  and	  inhibition	  of	  the	  trigeminal	  nerve	  (decrease	  in	  substance	  P).	  While	  activation	  of	  the	  5-­‐HT4	  receptors	  has	  been	  reported	  to	  cause	  intracranial	  vasoconstriction.36-­‐37	  
4.4	  Topiramate	   Figure	  11:	  Structure	  of	  Topiramate	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trigeminal	  nerve,	  which	  in	  turn	  reduces	  the	  release	  of	  neurotransmitters	  (substance	  P,	  NO,	  CGRP)	  that	  result	  in	  nociception	  (pain).38	  	  
4.5	  Dihydroergotamine	  	   Figure	  12:	  Structure	  of	  Dihydroergotamine	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4.6	  Propranolol	   Figure	  13:	  Structure	  of	  Propranolol	  
	  
	   	  	  	  	  	  	  	  	  	  	   	  
	  Propranolol	  is	  a	  beta-­‐1	  blocker	  that	  prevents	  migraine	  activity	  by	  reducing	  the	  neuronal	  firing	  rate	  of	  noradrenergic	  neurons.	  Propranolol	  is	  also	  a	  5-­‐HT2B,C	  receptor	  antagonists	  that	  causes	  cranial	  vasoconstriction	  and	  increased	  cranial	  capillary	  permeability.	  40	  
	  
4.7	  Chemical	  Structure	  Analysis	  of	  Vasoconstrictor	  Drugs	  and	  Ginger	  
	  At	  the	  beginning	  of	  this	  project,	  a	  literature	  review	  was	  done	  to	  understand	  the	  role	  of	  compounds	  in	  ginger	  against	  migraines.	  The	  literature	  findings	  demonstrated	  that	  ginger	  acts	  as	  a	  vasoconstrictor,	  which	  relieves	  migraines.	  These	  discoveries	  led	  to	  the	  hypothesis	  that	  the	  compounds	  in	  ginger	  must	  have	  structural	  similarities	  to	  popular	  vasoconstrictor	  drugs.	  	  However,	  based	  on	  the	  findings	  shown	  in	  Table	  3,	  it	  can	  be	  seen	  that	  the	  bioactive	  compounds	  in	  ginger	  share	  no	  structural	  similarities	  to	  the	  vasoconstrictor	  drugs	  used	  to	  treat	  migraines.	  
	  Table	  3:	  Structural	  Analysis	  of	  Vasoconstrictor	  Drugs	  and	  Ginger	  
Compound	  	   Structural	  Analysis	  

















	   • Tetradecan-­‐3,5-­‐dione	  
• 4-­‐Hydroxy-­‐3-­‐methoxyphenyl	  
Vasoconstrictor	  Drugs	   	  
Rizatriptan	   • 1,2,4-­‐	  Triazole	  
• Indole	  	  
• N,N-­‐dimethylethanamine	  
Sumatriptan	   • N-­‐methyl	  sulfonamidomethyl	  
• Indole	  
• N,N-­‐	  dimethylethanamine	  








Elavil	   • Dibenzocycloheptene	  
• N,N-­‐dimethylpropan-­‐1-­‐amine	  
Metoclopramide	   • 2-­‐Methoxybendamize	  
• N,N-­‐diethylethaneamine	  
Topiramate	   • Methylsulfamate	  
• Pinacol	  
• Tetrahydropyran	  
Dihydroergotamine	   • Indole	  
• Phenyl	  	  
Propranolol	   • Naphthalene	  
• Isopropylamine	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CHAPTER	  5:	  DISCUSSION	  OF	  RESULTS	  AND	  CONCLUSION	  
 
5.1	  Discussion	  	  	  The	  origin	  and	  mechanism	  of	  migraines	  are	  not	  fully	  understood;	  Current	  research	  suggests	  that	  a	  migraine	  is	  caused	  by	  vasodilation	  (via	  activation	  of	  5-­‐HT	  receptors).	  	  Activation	  of	  5-­‐HT	  receptor	  results	  in	  cerebral	  hyperemia	  (increased	  blood	  flow	  to	  the	  brain)	  and	  increased	  nitric	  oxide	  synthase	  (NOS)	  expression	  in	  trigeminal	  ganglion	  and	  trigeminal	  nucleus	  caudalia.14	  NOS	  allows	  the	  release	  of	  NO	  (potent	  vasodilator)	  from	  neurons.	  Once	  released,	  NO	  diffuses	  back	  into	  the	  presynaptic	  terminal	  to	  release	  neurotransmitters	  such	  as	  substance	  P	  (pain)	  and	  CGRP	  (potent	  vasodilator).	  15,	  16	  NO	  has	  also	  been	  shown	  to	  cause	  depolarization	  of	  cortical	  neurons	  from	  the	  occipital	  lobe	  (back	  of	  the	  head)	  toward	  the	  frontal	  lobe.9	  Depolarization	  of	  the	  cortical	  neurons	  results	  in	  sensory	  or	  motor	  impairment	  (loss	  of	  vision,	  speech,	  and	  senses).10	  To	  relieve	  the	  pain	  and	  symptoms,	  patients	  are	  treated	  with	  vasoconstrictor	  drugs	  as	  shown	  in	  Table	  3.	  	  The	  bioactive	  compounds	  in	  ginger	  are	  also	  not	  fully	  understood,	  but	  many	  studies	  have	  shown	  that	  ginger	  can	  alleviate	  migraine	  pain	  by	  the	  reduction	  of	  NOS	  expression	  resulting	  in	  the	  inhibition	  of	  NO.	  	  Ginger	  has	  also	  been	  reported	  to	  act	  as	  a	  partial	  HT1A	  agonist,	  which	  induces	  vasoconstriction	  and	  reduces	  inflammation	  by	  inhibition	  of	  substances	  (CGRP,	  Substance	  P,	  NO)	  from	  trigeminal	  nerve	  causing	  redistribution	  of	  blood	  flow	  resulting	  in	  alleviation	  of	  migraine	  pain.32	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Ginger’s	  ability	  to	  act	  as	  a	  vasoconstrictor	  has	  led	  to	  the	  hypothesis	  that	  the	  bioactive	  compounds	  in	  ginger	  must	  have	  structural	  similarities	  to	  popular	  vasoconstrictor	  drugs.	  Through	  further	  research,	  this	  study	  has	  shown	  that	  the	  bioactive	  compounds	  in	  ginger	  share	  no	  structural	  similarities	  with	  vasoconstrictor	  drugs	  used	  to	  treat	  migraines	  as	  shown	  in	  Table	  3.	  	  	  
5.	  2	  Conclusions	  and	  Future	  Work	  
	  Most	  research	  studies	  suggest	  that	  migraines	  are	  caused	  by	  vasodilation,	  which	  is	  not	  always	  the	  case.	  A	  migraine	  can	  result	  from	  genetic	  and	  environmental	  factors,	  which	  play	  a	  role	  in	  the	  severity	  of	  the	  condition.	  	  Further	  research	  should	  be	  done	  to	  gain	  a	  better	  understanding	  of	  the	  mechanisms	  of	  migraines.	  Additionally,	  researchers	  should	  continue	  to	  investigate	  the	  bioactive	  compound	  in	  ginger,	  because	  only	  31	  out	  of	  108	  compounds	  in	  ginger	  have	  been	  identified	  and	  14	  bioactive	  compounds	  have	  been	  found,	  which	  indicates	  that	  the	  unknown	  compounds	  may	  help	  clarify	  the	  mechanism	  of	  ginger	  against	  migraines.	  	  	  
	  Moreover,	  future	  researchers	  should	  consider	  comparing	  the	  effects	  of	  vasoconstrictor	  drugs	  and	  ginger	  on	  cerebral	  arteries.	  The	  findings	  of	  these	  experiments	  may	  help	  to	  explain	  ginger's	  ability	  to	  alleviate	  migraine	  pain.	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